Abcam (LON:ABC)‘s stock had its “add” rating reissued by equities research analysts at Peel Hunt in a research report issued to clients and investors on Tuesday, ThisIsMoney.Co.Uk reports.
A number of other analysts have also commented on ABC. Panmure Gordon lowered Abcam to a “sell” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. dropped their price target on Abcam from GBX 1,144 ($15.05) to GBX 1,134 ($14.92) and set a “neutral” rating for the company in a research note on Monday, September 16th. Royal Bank of Canada dropped their price target on Abcam from GBX 1,300 ($17.10) to GBX 1,250 ($16.44) and set a “sector performer” rating for the company in a research note on Wednesday, December 18th. Finally, Liberum Capital reaffirmed a “hold” rating and issued a GBX 1,370 ($18.02) price target (up previously from GBX 1,230 ($16.18)) on shares of Abcam in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of GBX 1,276.80 ($16.80).
ABC stock traded up GBX 7 ($0.09) on Tuesday, reaching GBX 1,407 ($18.51). The company’s stock had a trading volume of 70,217 shares, compared to its average volume of 497,233. The business has a fifty day simple moving average of GBX 1,371.86 and a two-hundred day simple moving average of GBX 1,270.12. Abcam has a 12-month low of GBX 1,058 ($13.92) and a 12-month high of GBX 1,523 ($20.03). The firm has a market cap of $2.89 billion and a PE ratio of 64.54.
In other Abcam news, insider Alan Thomas Hirzel sold 25,381 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of GBX 1,171 ($15.40), for a total value of £297,211.51 ($390,964.89).
Abcam Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Featured Story: How to interpret the current ratio
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.